中文名 | 白术内酯 I |
英文名 | Atractylenolide-1 |
别名 | 白术油 白术内酯I 苍术内酯I 白术内酯 I 白术内酯Ⅰ(标准品) 白术内酯I(苍术内酯I) ATRACTYLENOLIDE I 白术内酯Ⅰ ATRACTYLENOLIDE I 白术内酯Ⅰ 标准品 |
英文别名 | Atractylenolide Ⅰ ATRACTYLENOLIDE-1 Atractylenolide-1 atractylenolide I 8,9-Dehydroasterolide Eudesma-4(15),7(11),8-trien-12-olide 3,8aβ-Dimethyl-5-methylene-2,4,4aα,5,6,7,8,8a-octahydronaphtho[2,3-b]furan-2-one (4aS,8aS)-4a,5,6,7,8,8a-Hexahydro-3,8a-dimethyl-5-methylenenaphtho[2,3-b]furan-2(4H)-one (4aS,8aS)-3,8a-dimethyl-5-methylidene-4a,5,6,7,8,8a-hexahydronaphtho[2,3-b]furan-2(4H)-one Naphtho[2,3-b]furan-2(4H)-one,4a,5,6,7,8,8a-hexahydro-3,8a-dimethyl-5-methylene-, (4aS,8aS)- |
CAS | 73069-13-3 |
化学式 | C15H18O2 |
分子量 | 230.3 |
InChI | InChI=1/C15H18O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h8,12H,1,4-7H2,2-3H3/t12-,15+/m0/s1 |
InChIKey | ZTVSGQPHMUYCRS-SWLSCSKDSA-N |
密度 | 1.12 |
熔点 | 121-123 °C(Solv: ligroine (8032-32-4)) |
沸点 | 405.0±44.0 °C(Predicted) |
比旋光度 | (c, 0.01 in MeOH)+222 |
闪点 | 170℃ |
蒸汽压 | 9.08E-07mmHg at 25°C |
溶解度 | 甲醇: 可溶物1mg/mL,澄清,无色 |
折射率 | 1.554 |
存储条件 | 2-8°C |
外观 | 白色针状结晶 |
物化性质 | 类白色结晶粉末,可溶于甲醇、乙醇、DMSO等有机溶剂,来源于白术AtractylodesmacrocephalaKoidz.。 |
MDL号 | MFCD09037395 |
体外研究 | Atractylenolide I (40, 60, 80, 100, 120, 150 μM) dose- and time-dependently reduces the cell viability in human A375 melanoma cells after treatment for 24, 48 and 72 hours. Atractylenolide I (50 and 100 μM) induces apoptosis of A375 cells in a dose-dependent manner at 48 h of treatment. Atractylenolide I (100 μM) significantly reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, without effect on total JAK2 and STAT3. Furthermore, Atractylenolide I inhibits the mRNA expression of STAT3-targeted genes, including Bcl-xL, MMP-2 and MMP-9. Atractylenolide I (up to 100 μM) shows no toxicity in normal cells. Atractylenolide I (25, 50 μM) decreases the Ox-LDL induced TNF-α, IL-6 and NO production in VSMCs. Atractylenolide I (12.5, 25 or 50 μM) significantly reduces the level of MCP-1 and inhibits Ox-LDL-induced VSMCs proliferation and migration. Atractylenolide I (25, 50 μM) inhibits positive staining of foam cells, and also significantly decreases lipid accumulation. Atractylenolide I (50 μM) suppresses p38MAPK and NF-κB p65 expression in VSMCs stimulated by Ox-LDL. Atractylenolide I (1, 10, 100 μM) downregulates paclitaxel-induced expression of VEGF and survivin via MyD88-dependent TLR4 signaling in EOC cells. |
体内研究 | Atractylenolide I (5, 10 or 20 mg/kg, p.o.) restores the decreased body weight in mice subjected to chronic unpredictable mild stress (CUMS). Atractylenolide I alleviates CUMS-induced depressive-like behavior, attenuates CUMS-induced imbalances in hippocampal neurotransmitter levels and reduces CUMS-induced increases in hippocampal pro-inflammatory cytokine levels and in the NLRP3 inflammasome in the hippocampi of mice. |
WGK Germany | 3 |
参考资料 展开查看 | 1. 邸思蓉 王雪 王灿灿 等. HPLC法同时测定肝炎康散中四种有效成分及指纹图谱研究[J]. 沈阳药科大学学报 2019 36(04):308-314. 2. 沈建涛, 张振凌. 白术炮制品中白术内酯Ⅰ、Ⅲ含量随放置时间变化的研究[J]. 时珍国医国药, 2014, 025(008):1873-1875. 3. 邓颂, 王爱萍, 陈曦,等. 黄芪白术汤下调miR-31-5p/STAT3环路抑制结肠炎相关性结肠癌进程[J]. 中国药理学通报, 2019, v.35(09):134-139. 4. 张东 周其.HPLC法测定白术药材中白术内酯Ⅰ和白术内酯Ⅲ含量[J].北方药学 2017 14(03):1-2. 5. 王建成. 白术中白术内酯Ⅰ,Ⅱ,Ⅲ提取工艺优选[J]. 中国实验方剂学杂志, 2015. 6. 李红英,龙澜,程新华,李亚杰,黄建民,帅超群.白术药材中白术内酯Ⅰ和白术内酯Ⅲ含量的测定[J].湖北民族学院学报(自然科学版),2013,31(02):142-144. 7. 欧阳丽敏, 王新宏, 朱思敏,等. 基于AHP-CRITIC法探讨英山茅苍术最佳采收期[J]. 中成药, 2020, 042(003):708-713. 8. 李春花, 李佳佳, 顿佳颖,等. 提取-共沸精馏耦合技术提取白术、桂枝挥发油工艺优化[J]. 中成药, 2019, 41(05):1132-1135. 9. 丁逸雪 徐继校 吴威 等. HPLC法同时测定白术中4种倍半萜[J]. 中成药 2020 042(004):927-931. 10. 陈文婷, 陈阳, 崔波,等. 气相色谱"一测多评"用于苍术多成分含量测定的可行性研究[J]. 中国中药杂志, 2018, 043(003):551-556. 11. 李琴瑜, 吴卫刚, 崔波, et al. 高效液相色谱法结合多元统计分析用于苍术药材的质量评价[J]. 药物分析杂志, 2018, v.38(04):56-66. 12. Wang, Qian, et al. "Content determination of the major constituents of Yinchenzhufu decoction via ultra high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry." Journal of pharmaceutical and biomedical analysis 13. Wang, Qian, et al. "Content determination of the major constituents of Yinchenzhufu decoction via ultra high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry." Journal of pharmaceutical and biomedical analysis 14. [IF=3.935] Qian Wang et al."Content determination of the major constituents of Yinchenzhufu decoction via ultra high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry."J Pharmaceut Biomed. 2013 Apr;77:88 15. [IF=4.96] Yangyang Guo et al."Inhibition of proliferation-linked signaling cascades with atractylenolide I reduces myofibroblastic phenotype and renal fibrosis."Biochem Pharmacol. 2021 Jan;183:114344 16. [IF=4.36] Xiaoli Zhao et al."Transcriptomic study of the mechanism by which the Kai Yu Zhong Yu recipe improves oocyte quality in a stressed mouse model."J Ethnopharmacol. 2021 Oct;278:114298 17. [IF=4.032] Qiu-yue Xiao et al."A network pharmacology-based study on key pharmacological pathways and targets of Qi Fu Yin acting on Alzheimer's disease."Exp Gerontol. 2021 Jul;149:111336 18. [IF=3.205] Jie Tang et al."Metabolite profiling of Shuganzhi tablets in rats and pharmacokinetics study of four bioactive compounds with liquid chromatography combined with electrospray ionization tandem mass spectrometry."J Chromatogr B. 2021 Aug;1179:122827 19. [IF=4.759] Gao-Yan Tong et al."Analysis of active compounds and geographical origin discrimination of Atractylodes macrocephala Koidz. by using high performance liquid chromatography-diode array detection fingerprints combined with chemometrics."JOURNAL OF CHROMATOGR |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!